BackPacific Biosciences of California Overview

Pacific Biosciences of California Common Stock

Latest common stock for PACB: $0.

Get informed when a big investor buys or sells

+ Follow
Common Stock
$0.00
100.00% YoYΔ $-300000.00 vs prior year quarter

Peer average

Loading

Pacific Biosciences of California Common Stock History

Loading

Pacific Biosciences of California vs. peers: Common Stock Comparison

Loading

Pacific Biosciences of California Common Stock Growth (YoY per quarter)

Latest change versus the prior comparable period (same company). Positive growth indicates new issuance/dilution; negative growth indicates reductions/buybacks.

Loading

Pacific Biosciences of California (PACB) FAQ

As of the most recent data (June 2026), PACB shows a common stock of $0. That compares with $300K in the prior-year period — down 100.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PACB's common stock is now $0 (was $300K) — a 100.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Pacific Biosciences of California is outperforming or lagging.

Tracking PACB's common stock over time shows whether Pacific Biosciences of California is scaling, shrinking, or reshaping that part of the business. The current reading is $0 That compares with $300K in the prior-year period — down 100.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this common stock page, Stockcircle has Pacific Biosciences of California's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect common stock (currently $0) with ownership activity and broader fundamentals.

Pacific Biosciences of California's common stock is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.